MDMA-Assisted Massed Exposure Therapy for PTSD
Key facts
- Who runs it
- Emory University
- Where
- Atlanta, United StatesSee the site
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 200 people, planned
- Started
- Jul 2026
- Expected to end
- Jan 2030
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- 3,4-Methylenedioxymethamphetamine (MDMA)
- Placebo
- Massed Prolonged Exposure (PE)
- Record updated
- 26 May 2026
Who can take part
- Age
- 21 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 28 criteriaShow less
Who can take part
- PTSD diagnosis as assessed by Clinician-Administered Posttraumatic Stress Scale for DSM-5 - Revised (CAPS-5-R)
- Able to speak and read English (due to standardization of outcome measures)
- Willing to sign a release for the investigators to communicate with their primary care or mental health providers if indicated
- Able to swallow pills
- Agree to have study visits video and/or audio recorded, including Experimental Session, assessments, and non-drug therapy sessions
- Willing to provide a contact (relative, spouse, close friend, or another support person) who is willing and able to be contacted by the investigators
- Agree to inform the investigators within 48 hours of any medical conditions and procedures
- If able to become pregnant, must have a negative pregnancy test before study entry, at study entry, and before the Medicine Session. Must agree to use adequate birth control for a month before the Medicine session and through 10 days after the Medicine Session
- Agree to the following lifestyle modifications: comply with requirements for fasting and refraining from certain medications before the Medicine Session, and not participating in any other interventional clinical trials during the duration of the study, are driven home or to a hotel after the Medicine Session, and commit to medication dosing, therapy, and study procedures
Who cannot take part
- Have previously participated in a Multidisciplinary Association for Psychedelic Studies (MAPS) sponsored MDMA clinical trial
- Have a history of any medical condition that could make receiving MDMA dangerous because of increases in blood pressure and heart rate or any medical condition the study physician believes would pose a safety risk or interfere with the effects of the treatment. Any medical disorder judged by the investigator to significantly increase the risk of MDMA administration by any mechanism is exclusionary
- Require the use of concomitant medications that could impact the effects or safety of MDMA during the Medicine Session
- Have engaged in ketamine-assisted therapy or used ketamine within 12 weeks of enrollment
- Have hypersensitivity to any ingredient of the Investigational Medicinal Product (IMP)
- Upon review of medical or psychiatric history and psychiatric assessment, have any current or past diagnosis that would be considered a risk to participating in the study
- Requires ongoing psychiatric medication use with certain exceptions. Individuals may decide to taper psychiatric medications under the guidance of their local provider
- Have any unstable medical condition that would interfere with participation
- Have uncontrolled hypertension) documented on three separate occasions
- Have Wolff-Parkinson-White syndrome or any other accessory pathway that has not been successfully eliminated by ablation
- Have a history of ever having ventricular arrhythmia or any other abnormal heart rhythm that the study physician believes would pose a significant risk of participation
- Have symptomatic liver disease or significant liver enzyme elevations
- Have a history of hyponatremia or hyperthermia
- Have a history of additional risk factors for Torsade de Pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)
- Are not able to give adequate informed consent
- Have any current problem which, in the opinion of the investigator or study physician, might interfere with participation
- Have an abnormal finding on electrocardiogram
- Weigh less than 48 kilograms (105 lbs.)
- Are pregnant or nursing
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 21 and 70 years old?
Where in United States
- Emory Brain Health CenterAtlanta, United StatesContact: Jessica Maples-Keller, PhDTaking people
About the trial
What the trial wants to find out
The goal of this clinical trial is to investigate the efficacy of 3,4-methylenedioxy-methamphetamine hydrochloride (MDMA) combined with Massed Prolonged Exposure (PE) therapy for the treatment of posttraumatic stress disorder (PTSD) in adult participants diagnosed with PTSD. This randomized, placebo-controlled trial will enroll 95 participants.
Read full original descriptionShow less
The main questions it aims to answer are:
* Does the combination of PE + MDMA lead to greater reduction in PTSD symptom severity from pre-treatment to one-month follow-up compared to PE + placebo? * Does PE + MDMA improve response efficiency and durability of PTSD symptom improvement compared to PE + placebo? * Does MDMA + PE enhance extinction retention and reduce amygdala threat reactivity, and are these changes associated with improved PTSD outcomes?
Participants will:
* Receive 10 sessions of Massed Prolonged Exposure therapy over two weeks * Be administered either 100 mg of MDMA or a placebo at Visit 2 * Undergo blinded independent evaluator assessments using the Clinician-Administered PTSD Scale for DSM-5-R (CAPS-5-R) at the one-month posttreatment follow-up
The 2 groups in the trial
- MDMA groupTreatment being tested
Treatment: 3,4-Methylenedioxymethamphetamine (MDMA) and Massed Prolonged Exposure (PE)
- Standard of CarePlacebo, for comparison
Treatment: Placebo and Massed Prolonged Exposure (PE)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Criteria questions
- Built from NCT07288151, who can take part
- Record updated
- 26 May 2026